Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
about
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsEngineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of BiotherapeuticsImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsNeonatal Fc receptor and IgG-based therapeuticsThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapyNovel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonistA novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.Molecularly defined antibody conjugation through a selenocysteine interface.Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.Recombinant FIXFc: a novel therapy for the royal disease?Neonatal Fc receptor: from immunity to therapeuticsComparison of FcRn- and pIgR-mediated transport in MDCK cells by fluorescence confocal microscopy.In vitro selection of a peptide antagonist of growth hormone secretagogue receptor using cDNA display.Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.Soluble monomeric IgG1 Fc.Generation and Characterization of an IgG4 Monomeric Fc Platform.An engineered selenocysteine defines a unique class of antibody derivatives.Pharmacokinetics of recombinant bifunctional fusion proteins.Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tagAdvances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.Current options and new developments in the treatment of haemophilia.Fusion protein linkers: property, design and functionality.Advances in the treatment of inherited coagulation disorders.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption.Bioavailability of therapeutic proteins by inhalation--worker safety aspects.Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Half-life extended biotherapeutics.Bioconjugation - using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers.The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.Extended half-life clotting factor concentrates: results from published clinical trials.Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion proteinCoagulation Factor IX for Hemophilia B Therapy.Pharmacokinetic and pharmacodynamic properties of a new long-acting granulocyte colony-stimulating factor (HM10460A) in healthy volunteers.
P2860
Q26801319-2A01513F-06AA-4332-BDFF-D221D8EB23B4Q26822421-664AACD0-BB56-4055-9EEF-8475B935851FQ27677555-9FF7A350-438D-4FCF-A377-9182A6F43ACFQ28072319-D9DBBE88-7C00-48F7-AF0A-66C96759C798Q28252134-912CE66E-F9C2-42D3-B35E-E7A097BC401CQ28257521-1032F281-1F71-442D-A978-CCF307B23899Q28475510-0D368899-E94E-4808-8B1D-9655D688B4F4Q30426130-56B7DA24-72EE-4B39-A6B0-2B587CD8BD38Q30539596-17891E79-C9CF-4152-9DED-70C4B4BA3B0BQ33381465-B935E428-621D-43E1-A4F6-44CA4835EBEEQ33675575-1239685E-D7B1-45D9-AF26-9731CAB5D23EQ33911461-BAFEE3BA-99C6-4295-B9CF-BB29B5DA25F7Q33968782-C5CF97E3-EE62-431D-B93C-2FE78E1A2630Q34268801-069478CA-F4F7-458F-9C51-C3F0E913881CQ34287580-62454C6D-5783-4529-B771-863F378B0842Q34313652-54AF7D48-76AE-4EFD-8793-D55E60665D40Q34545655-C2D6C3C5-537A-4D12-8378-AA9C6A7FDBACQ35692016-BCD2BB6B-C7E5-4609-A14B-1A2E67F0B05AQ35913495-759C0A2A-7224-46FF-A623-967018222F2BQ36003820-32D561DE-61FE-4F4E-9E87-4A79BF09CA60Q36091637-1F0099E4-BFBD-4DA7-92E4-D871C8E65D7CQ36843553-C9D5CFFC-C598-4D6D-A09B-3E43346976A3Q37033032-82874BD2-9FEE-4D5A-8F9D-5A5DE7C0ACA6Q37117619-29C9D1C4-F5DB-4F04-AE61-089F6E4EF89DQ37381361-E9D7108D-98AA-43AC-96EA-CB200B88165BQ37841547-7E0C1146-DD38-4FBC-9CE2-0920B221EE0BQ38048516-00C8250D-0EDB-4BBE-8B94-A84829B76060Q38100271-72650A38-3634-42C9-B98A-6790D72B163BQ38110433-2A38A8DF-0952-433D-BFA2-093EF2C98924Q38168594-4D37B70E-D84F-4BC9-9C59-7EAF5E9A15A8Q38222723-305195A6-33F8-435C-866A-2F6B274F88ABQ38266890-7133BCFF-D829-4B39-931E-A9818DE3834DQ38574414-BA07D13A-3EA6-45F5-A788-EAC21369668BQ38770067-B8CBEB0F-D916-41C5-9F21-91559159298EQ38909537-BAD12B7A-8860-43D9-8070-0FFED8CF2643Q39558945-D453DC0F-9CB7-4C4A-BE4A-2CA0B0B15ED1Q39609294-03EB91C9-612B-4D5A-80C8-D9FF14BB4708Q41611929-698A1F78-A2F2-46E5-90C1-AB34B2C46F79Q42256024-E5F4287C-830F-4391-A2ED-A52FE7257331Q44555003-DEB05BC6-3BFC-48C0-833D-396C6285FDF7
P2860
Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@ast
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@en
type
label
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@ast
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@en
prefLabel
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@ast
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@en
P2093
P1433
P1476
Monomeric Fc fusions: impact o ...... ivity of protein therapeutics.
@en
P2093
Alan J Bitonti
Jennifer A Dumont
Robert T Peters
Susan C Low
P2860
P304
P356
10.2165/00063030-200620030-00002
P577
2006-01-01T00:00:00Z
P6179
1050131829